A Multicentre, Single Arm, Non-interventional, Real-world Study to Assess Demographic Characteristics and Patient Reported Outcomes in Patients With Severe Eosinophilic Asthma Treated With Benralizumab in China
Patients are eligible for inclusion only if all of the following criteria are met:
Aged ≥12 years at the time of signing the informed consent form.
Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician.
For the patients who had received benralizumab prior to enrolment, the interval between the Index date and the date of enrolment must \<=4 weeks;
ACQ-6 score within 7 days prior to index date is required.
Patients must have a current prescription for benralizumab with planned initiation of therapy.
Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures.
You may not be if
1. Patients currently participating in any other interventional clinical trial.
2. Known history of allergy or reaction to any component of benralizumab.
3. Malignancy of any kind.
4. Pregnant, breast-feeding or intending to become pregnant during the study period